Taken together, the results suggest a complex interaction between MET and EGFR in NSCLC in the presence of EGFR TKIs and provide unique insight into potential resistance mechanisms and management strategies in EGFR/METex14-altered lung cancers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.